48-week data on raltegravir in naive patients.
D019380:Anti-HIV Agents / Q000008:administration & dosage; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009930:Organic Chemicals / Q000009:adverse effects / Q000627:therapeutic use*; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D009930:Organic Chemicals; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium